[{"id":"098d33f4-6759-4d74-9fca-b364e3f3f2d4","acronym":"PRORADIUM","url":"https://clinicaltrials.gov/study/NCT02925702","created_at":"2021-10-27T06:44:55.098Z","updated_at":"2024-07-02T16:36:50.907Z","phase":"","brief_title":"PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.","source_id_and_acronym":"NCT02925702 - PRORADIUM","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" AR","pipe":" | ","alterations":" AR amplification • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR amplification • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xofigo (radium Ra-223 dichloride)"],"overall_status":"Unknown status","enrollment":" Enrollment 161","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2020-01-27"},{"id":"d865a9f7-2178-4ced-881c-a75158e29a4f","acronym":"PROSENZA","url":"https://clinicaltrials.gov/study/NCT02922218","created_at":"2021-01-18T14:20:52.861Z","updated_at":"2024-07-02T16:36:50.930Z","phase":"","brief_title":"PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.","source_id_and_acronym":"NCT02922218 - PROSENZA","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • AR • ERG","pipe":" | ","alterations":" AR amplification • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression","tags":["PTEN • AR • ERG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR amplification • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Unknown status","enrollment":" Enrollment 187","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"1a7ccaaf-9044-4f2f-ae35-54a15ea11dd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01393730","created_at":"2021-01-18T05:43:26.209Z","updated_at":"2024-07-02T16:37:13.008Z","phase":"Phase 2","brief_title":"Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT01393730","lead_sponsor":"Mary-Ellen Taplin, MD","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR T878A • AR amplification","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR T878A • AR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 03/15/2017","study_completion_date":" 03/15/2017","last_update_posted":"2018-03-15"}]